Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients

Overview

This is a phase II study assessing the activity and safety of metronomic chemotherapy with cyclophosphamide and capecitabine and vinorelbine in advanced breast cancer patient in four different cohort of patients:

1. Untreated (naïve) patients with endocrine responsive disease

2. Pretreated patients with endocrine responsive disease

3. Untreated (naïve) patients with triple negative disease

4. Pretreated patients with triple negative disease The primary endpoint will be the progression-free survival

Full Title of Study: “A Phase II Study of Metronomic Oral Chemotherapy With Cyclophosphamide Plus Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2020

Detailed Description

This is an institutional, monocentric, open-label, phase II study of oral "metronomic" Vinorelbine plus Capecitabine and Cyclophosphamide (VEX) in patients with advanced breast cancer .

Patients will receive the combination regimen as follow:

Cyclophosphamide 50 mg daily Capecitabine 500 mg, thrice daily Vinorelbine 40 mg orally thrice a week

Four independent cohorts of patients will be evaluated in the study:

1. Untreated (naïve) patients with endocrine responsive disease

2. Pretreated patients with endocrine responsive disease

3. Untreated (naïve) patients with triple negative disease

4. Pretreated patients with triple negative disease Combination will be administered until disease progression or unacceptable toxicity.

The primary endpoint will be to assess the Time to progression (TTP) of VEX combination in the four different cohorts

Interventions

  • Drug: Vinorelbine
    • Metronomic Vinorelbine 40 mg orally thrice a week
  • Drug: Capecitabine
    • Metronomic Capecitabine 500 mg, thrice daily
  • Drug: Cyclophosphamide
    • Metronomic Cyclophosphamide 50 mg daily

Arms, Groups and Cohorts

  • Experimental: Metronomic VEX
    • Metronomic VEX (Oral Cyclophosphamide 50 mg daily continuous, Oral Capecitabine 500 mg, thrice daily continuous, Oral Vinorelbine 40 mg day 1,3 and 5 every week

Clinical Trial Outcome Measures

Primary Measures

  • Time to progression (TTP)
    • Time Frame: 28 days
    • the time between the first study dose administration and the date of progression of the disease or cancer-related death, whichever occurs first

Participating in This Clinical Trial

Inclusion Criteria

1. Pre- or post-menopausal women (age ≥18 years) with histologically or cytologically (cell block) proven, locally advanced (inoperable) or metastatic breast carcinoma. Immunohistochemical evaluation of estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor (EGFR) according to European Institute of Oncology guidelines is mandatory.

2. Patients with HER2 overexpressed tumors, are eligible if they had received previous trastuzumab therapy for advanced disease, and/or a treatment with anti HER2 targeted therapy.

3. Patients fulfilling one of the following criteria:

  • Patients with measurable disease as per RECIST 1.1 criteria. This is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as 20 mm with conventional techniques or as 10 mm with spiral CT scan
  • Patients with bone lesions, lytic or mixed (lytic + sclerotic), in the absence of measurable disease as defined by RECIST 1.1 criteria. Bone lesions must be evaluable by plain CT or MRI. Patients with lesions identified only on radionucleotide bone scan are not eligible.

4. Patients may have received any primary and/or adjuvant therapies, as any previous lines of chemotherapy and endocrine therapy for advanced disease. Patients may have received metronomic capecitabine, methotrexate and cyclophosphamide in adjuvant setting at least 12 months before study entry

5. Previous treatment with capecitabine, cyclophosphamide and vinorelbine not in metronomic schedule for advanced disease is allowed, provided that the patient has progressive disease at study entry and the patients should not be defined as "refractory" to treatments (Pathological Response or Complete Response or Stable Disease > 6 months).

6. Patients may have had previous hormonal therapy as treatment of metastatic disease provided that the patient has progressive disease at study entry. Hormonal therapy must be discontinued prior to study entry, excluding Luteinizing Hormone-Releasing Hormone (LHRH) analogue.

7. Life expectancy greater than 6 months.

8. Eastern Cooperative Oncology Group (ECOG) Performance Status performance status <2

9. Patients must have normal organ and marrow function as defined below:

  • leukocytes ≥ 3,000/μL
  • absolute neutrophil count ≥ 1,000/μL
  • platelets ≥ 100,000/μL
  • Haemoglobin ≥ 10 g/dl
  • total bilirubin within normal institutional limits
  • Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) ≤ 2 X institutional upper limit of normal
  • creatinine within normal institutional limits OR
  • creatinine clearance ≥ 60 mL/min/1.73 m for patients with creatinine levels above institutional normal

10. Geographically accessible for follow up.

11. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

1. Previous metronomic chemotherapy for advanced disease with capecitabine, cyclophosphamide and vinorelbine

2. Patients defined as "refractory" to capecitabine, cyclophosphamide and vinorelbine (Progression Disease or Stable Disease < 6 months).

3. Presence of symptomatic cerebral or leptomeningeal involvement.

4. Previous or concomitant other malignancy except basal or squamous cell carcinoma of the skin or adequately treated in situ carcinoma of the cervix.

5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

6. Malabsorption syndrome or disease affecting significantly gastrointestinal function or major resection of the stomach or proximal small bowel that could affect absorption of oral vinorelbine

7. Concurrent treatment with any other anti-cancer therapy except LHRH analogue.

8. Patients with pre-existing motor or sensory peripheral neuropathy grade 2 according to NCI criteria

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 99 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • European Institute of Oncology
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Marco Colleoni, MD, Principal Investigator, European Institute of Oncology
  • Overall Contact(s)
    • Emilia Montagna, MD, +390257489243, emilia.montagna@ieo.it

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.